loading page

Eribulin and irinotecan (ERII) for refractory or recurrent Ewing sarcoma: a retrospective study
  • +3
  • Jie Xu,
  • Kuisheng Liu,
  • Lu Xie,
  • Xin Sun,
  • Xin Liang,
  • Xiaodong Tang
Jie Xu
Peking University People's Hospital
Author Profile
Kuisheng Liu
Peking University People's Hospital
Author Profile
Lu Xie
Peking University People's Hospital
Author Profile
Xin Sun
Peking University People's Hospital
Author Profile
Xin Liang
Peking University People's Hospital
Author Profile
Xiaodong Tang
Peking University People's Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Background: The effectiveness of eribulin and irinotecan in treatment of xenograft models of Ewing sarcoma is well-established but no clinical data has been reported. Methods: The medical records of patients treated for refractory or recurrent Ewing sarcoma with 1.4mg/m 2 D 1,8 eribulin and 20mg/m 2/d D 1-5,8-12 irinotecan at 21 day intervals (ERII) at Peking University People’s Hospital (PKUPH) were retrospectively reviewed. Results: A total of 17 patients with median age 18.6 years were treated with a total of 77 courses of ERII between February 2022 and February 2023. The objective response rate was 35.3%, disease control rate 58.9% and the median event-free survival (EFS) 2.07 months. 35.3% patients had 6 months EFS and overall survival was 66.9%. Grade 3 or 4 toxicities were observed in 37.6% courses and in 64.7% of the patients, with myelosuppression, especially neutropenia, being the most common and diarrhea / abdominal pain the second most common. Conclusions: The combination of eribulin and irinotecan as a second-line regimen is well-tolerated and shows promising efficacy. There is scope for further research into the synergistic mechanism of the two agents and into potential biomarkers.